

2018

**Technical manual  
for drug susceptibility  
testing of medicines  
used in the treatment  
of *tuberculosis***



World Health  
Organization



**Technical manual  
for drug susceptibility  
testing of medicines  
used in the treatment  
of *tuberculosis***

Technical manual for drug susceptibility testing of medicines used in the treatment of *tuberculosis*  
ISBN 978-92-4-151484-2

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition". Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions expected, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

WHO/CDS/TB/2018.24

Contents

**Acknowledgements..... vi**

**Abbreviations..... vii**

**Glossary of terms ..... ix**

**1. Introduction..... 1**

1.1 Background..... 1

1.2 Scope..... 2

1.3 Biosafety..... 2

1.4 Evidence basis for determining critical concentrations for DST ..... 3

1.5 Recommendations for DST ..... 4

1.5.1 First-line anti-TB agents ..... 4

1.5.2 Second-line anti-TB agents..... 6

**2. Susceptibility testing for anti-TB agents using solid media..... 11**

2.1 Proportion method using Löwenstein–Jensen medium..... 11

2.1.1 Principles..... 11

2.1.2 Preparing the medium..... 11

2.1.3 Anti-TB agents and critical concentrations for testing..... 12

2.1.4 Preparing the mycobacterial suspension..... 14

2.1.5 Diluting the suspension and inoculating the Löwenstein–Jensen medium..... 14

2.1.6 Incubation ..... 14

2.1.7 Examining the cultures ..... 15

2.1.8 Interpreting and reporting results..... 15

2.1.9 Quality control..... 16

2.2 Proportion method using Middlebrook 7H10 or 7H11 agar media ..... 16

2.2.1 Principles..... 16

2.2.2 Preparing the medium..... 16

2.2.3 Anti-TB agents and test concentrations ..... 17

2.2.4 Preparing the mycobacterial suspension..... 20

2.2.5 Diluting the suspension and inoculating the medium ..... 20

2.2.6 Incubation..... 21

2.2.7 Examining the cultures..... 21

2.2.8 Interpreting and reporting results..... 21

2.2.9 Quality control..... 22

<b>3. Susceptibility testing for anti-TB agents using liquid media.....</b>	<b>23</b>
3.1 Principles .....	23
3.2 Preparing the medium .....	23
3.2.1 Medium .....	23
3.3 Anti-TB agents and critical concentrations for testing .....	24
3.4 Preparing solutions of anti-TB agents .....	25
3.4.1 Using lyophilised agents.....	25
3.4.2 Using pure drug powders .....	25
3.5 Calculating the dilution factor for the MGIT medium.....	29
3.6 Adding an anti-TB agent to the medium .....	29
3.7 Preparing the mycobacterial inoculum .....	29
3.7.1 Using inoculum from the MGIT tube.....	29
3.7.2 Using inoculum from growth on solid media.....	30
3.7.3 Inoculation and incubation .....	31
3.7.4 Adding to and inoculating the MGIT medium .....	31
3.8. DST set carriers.....	31
3.8.1 Entering the DST set carrier into the MGIT instrument.....	31
3.9 Duration of the test.....	32
3.10 Interpreting and reporting results .....	32
3.10.1 Important considerations .....	32
3.11 Quality control .....	33
<b>4. Annexes.....</b>	<b>34</b>
Annex A. Storing stock cultures.....	34
Annex B. McFarland Turbidity Standards .....	34
Annex C. Quality control testing.....	35

## List of tables

Table 1. Critical concentrations (CC) for first-line medicines recommended for the treatment of drug-susceptible TB. ....	3
Table 2: Clinical interpretation table for first-line anti-TB medicines.....	5
Table 3. Critical concentrations (CC) and clinical breakpoints (CB) for medicines recommended for the treatment of RR-TB and MDR-TB. (Interim CC are highlighted in red) .....	8
Table 4. Clinical interpretation table for second-line anti-TB medicines.....	9
Table 5. Concentrations and solutions needed to prepare first- and second-line anti-tuberculosis agents for use with 500 mL of Löwenstein–Jensen medium.....	13
Table 6. Concentrations and solutions needed to prepare first- and second-line anti-tuberculosis (anti-TB) agents for use with 500 mL of 7H10 medium.....	18
Table 7. Concentrations and solutions needed to prepare first- and second-line antituberculosis (anti-TB) agents for use with 500 mL of 7H11 medium .....	19
Table 8 Quantifying and reporting the growth of bacteria on culture plates.....	21
Table 9. Reconstitution volumes and final concentrations for first-line anti-TB agents.....	24
Table 10. Reconstitution volumes and final concentrations for lyophilise second-line anti-TB agents available form BD.....	25
Table 11. Availability of pure powders from GDF and other manufacturers .....	26
Table 12. Concentrations and solutions needed to prepare second-line anti-TB agents for use with the BACTEC MGIT 960 system.....	27

## Acknowledgements

The development of this document was led by Christopher Gilpin with contributions from Alexei Korobitsyn, Lice Gonzales Angulo and Karin Weyer (WHO Global TB Programme) based on a draft document prepared by Salman Siddiqi (BD Fellow, USA).

## External Review Group

Daniela Cirillo (San Raffaele Scientific Institute, Milan, Italy); Soudeh Ehsani (WHO Regional Office For Europe, Copenhagen, Denmark); Ramona Groenheit (Public Health Agency of Sweden, Stockholm, Sweden); Rumina Hasan (The Aga Khan University, Karachi, Pakistan); Sven Hoffner (Karolinska Institutet, Stockholm, Sweden); Nazir Ismail (National Institute of Communicable Diseases, Johannesburg, South Africa); Claudio Köser (University of Cambridge, Cambridge, United Kingdom); Florian Maurer (National and Supranational Reference Center for Mycobacteria Research Center Borstel, Germany); Leen Rigouts (Institute of Tropical Medicine, Antwerp, Belgium); Thomas Shinnick (Independent consultant, USA); Elisa Tagliani (San Raffaele Scientific Institute, Milan, Italy); Jim Werngren (Public Health Agency of Sweden, Stockholm, Sweden).

## Acknowledgement of financial support

Funding from the United States Agency for International Development through USAID-WHO Consolidated Grant No. GHA-G-00-09-00003 / US2014-741 is also gratefully acknowledged.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_25542](https://www.yunbaogao.cn/report/index/report?reportId=5_25542)

